206-838-5110 ext. 102 general@etubics.com

Press Releases

Gilbert S. Omenn Joins Etubics Board of Directors

SEATTLE – Etubics Corporation announces the election of Gilbert S. Omenn, MD, PhD, to its Board of Directors. “Dr. Omenn is a welcome addition to Etubics' Board,” said Dr. Frank Jones, chief executive officer, chairman of the board and founder of Etubics. "His vast...

Etubics Platform Controls HIV and H1N1 Infection in Animal Model

SEATTLE (December 18, 2012) – Etubics Corporation, a clinical stage bio-pharmaceutical company with a proprietary platform vaccine technology that delivers a long lasting "active" immune response against diseases, announced that Vaccine has published a peer reviewed...

HPV Vaccine Enhances Treatment of HPV Expressing Cancer in Animals

SEATTLE (September 19, 2012) – Etubics Corporation, a clinical stage bio-pharmaceutical company with a proprietary platform vaccine technology that delivers a long lasting "active" immune response against diseases, and Sanford Research in South Dakota announced that...

Etubics AD5 Platform Overcomes AD5 Immunity in Multiple Studies

Clinical & Cellular Immunology Review Shows Company Can Break Ad5 Immunity Tolerance SEATTLE (December 21, 2011) – Etubics Corporation, a clinical stage bio-pharmaceutical company with a proprietary platform technology that can be used to rapidly develop both...

Etubics H1N1 Vaccine Inhibits Horizontal Transmission in Ferrets

Etubics Platform Enables the Rapid Production of H1N1 Vaccine, Making It Ideal for Pandemics SEATTLE (August 16, 2011) – Etubics Corporation, a clinical stage bio-pharmaceutical company with a proprietary platform technology that can be used to rapidly develop...

Etubics Awarded Grant for HPV Induced Cancers

SEATTLE (July 5, 2011) – Etubics Corporation, a clinical stage bio-pharmaceutical company with a proprietary platform technology that can be used to rapidly develop immunotherapeutics and preventive vaccines for a wide range of diseases, announced today that it was...

Categories

  • No categories

Archives

Media Contact:

Jen Hodson
NantWorks
562-397-3639
Press@NantHealth.com